Nuffield Department of Medicine receives funding to improve bowel cancer treatment — Oxford Cancer – Nuffield Department of Population Health

Uncategorized

We use cookies to ensure that we give you the best experience on our website. If you click ‘Accept all cookies’ we’ll assume that you are happy to receive all cookies and you won’t see this message again. If you click ‘Reject all non-essential cookies’ only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click ‘Find out more’ for information on how to change your cookie settings.
Bowel Cancer Funding
23 November 2022
The Leedham Lab in the Nuffield Department of Medicine (NDM) has been awarded over £2M from Cancer Research UK to develop a new tool that could help guide how bowel cancer patients are treated in the future.
Bowel cancer is the fourth most common cancer in the UK with nearly 43,000 people diagnosed every year. 
“Our understanding of the biology of bowel cancer is really advancing very rapidly, and this has been helped by the ability to examine samples of tumours with a wide range of molecular tools ,” explains Simon Leedham, Professor of Molecular and Population Genetics from the University of Oxford, and Honorary Consultant at the John Radcliffe Hospital.
Funding from Cancer Research UK has enabled the Leedham Lab NDM at Oxford University to develop a brand new molecular tool, which could lead to a step change in how to choose the best treatment for each patient at the right time.
Commenting on the tool, Prof Leedham added: “We believe that part of the reason some therapies fail is because cancer cells have the capacity to change their behaviour when they are exposed to chemotherapy. Whilst some cells will be killed, other cells within the tumour survive and can change their behaviour and appearance  – a leopard that can change its spots! This is known as cell plasticity. 
“Currently the only tool we have to understand whether a tumour is responding to our treatments is using radiology scanning to look for whole tumour shrinkage. However, this isn’t able to identify changes that occur at a cellular level.
We think we can use our new molecular tool to assess how different tumours respond to different chemotherapies and then use this measurement to help deliver more effective treatments in patients like Tammy
Simon Leedham, Professor of Molecular and Population Genetics from the University of Oxford, and Honorary Consultant at the John Radcliffe Hospital.
Tammy Holden-White was aged just 30 when she was given a diagnosis of stage 4 bowel cancer in 2018.
 Her son was seven months old when she was diagnosed. She has had major surgery, targeted treatments and has used her own experience as a patient in the hope of enriching and accelerating research.
 She said: “For me a ‘bad tummy’ throughout my teens was eventually found to be Crohn’s disease, which attacked and damaged my cells and led to bowel cancer by the time I was 30.
 
 “For patients, the lottery of whether your particular cancer will respond well to current treatments is stressful enough, and how long they will be effective and what might happen after that has so far been unknowable.”
– Tammy Holden-White 
Tammy is an advocate of patient consent for tissue use in research so that samples and data about a patient’s cancer can be shared among researchers, allowing the affected person to take a critical role in contributing to scientific discovery.
She added: “Every cancer patient carries priceless information about how to tackle cancer. Each time we allow samples of our blood or tissue to be shared with researchers, we share the clues that will one day crack the enigma.”
Publishing a paper? Just won an award? We can help promote your news and elevate the overall impact of your work.
Contact us at cancer@medsci.ox.ac.uk.

Polygenic risk scores only modestly improve the predictive power of the QCancer-10 non-genetic risk score for colorectal cancer.

The NIHR Oxford Biomedical Research Centre (BRC), a partnership between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, will receive £86.6m over the next five years to fund 15 research themes.

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

source

Leave a Reply

Your email address will not be published.